AU2021322114A1 - Multispecific binding agents and uses thereof - Google Patents

Multispecific binding agents and uses thereof Download PDF

Info

Publication number
AU2021322114A1
AU2021322114A1 AU2021322114A AU2021322114A AU2021322114A1 AU 2021322114 A1 AU2021322114 A1 AU 2021322114A1 AU 2021322114 A AU2021322114 A AU 2021322114A AU 2021322114 A AU2021322114 A AU 2021322114A AU 2021322114 A1 AU2021322114 A1 AU 2021322114A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021322114A
Other languages
English (en)
Inventor
Bryan Glaser
Bonnie HAMMER
Seema Kantak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2021322114A1 publication Critical patent/AU2021322114A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021322114A 2020-08-04 2021-08-03 Multispecific binding agents and uses thereof Pending AU2021322114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061112P 2020-08-04 2020-08-04
US63/061,112 2020-08-04
PCT/US2021/044356 WO2022031710A2 (en) 2020-08-04 2021-08-03 Multispecific binding agents and uses thereof

Publications (1)

Publication Number Publication Date
AU2021322114A1 true AU2021322114A1 (en) 2023-03-02

Family

ID=80120131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021322114A Pending AU2021322114A1 (en) 2020-08-04 2021-08-03 Multispecific binding agents and uses thereof

Country Status (7)

Country Link
US (1) US20240010751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192878A4 (cg-RX-API-DMAC7.html)
JP (1) JP7840312B2 (cg-RX-API-DMAC7.html)
CN (1) CN116390939A (cg-RX-API-DMAC7.html)
AU (1) AU2021322114A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188068A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022031710A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
IL314395A (en) * 2022-01-31 2024-09-01 Centessa Pharmaceuticals Uk Ltd Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses
EP4540290A4 (en) * 2022-06-14 2026-07-01 Invenra Inc Multi-species liaison agents targeting B7H3 and GD2, and their uses
AU2023383441A1 (en) * 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
US12110332B2 (en) 2017-11-20 2024-10-08 Taizhou Mabtech Pharmaceutical Co., Ltd. Bifunctional fusion protein targeting CD47 and PD-L1
CA3084626A1 (en) * 2017-12-04 2019-06-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
CA3187837A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Cd47 binding agents and uses thereof
CA3187850A1 (en) * 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
EP4475886A4 (en) * 2022-02-09 2026-03-18 Exelixis Inc MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES
EP4540290A4 (en) * 2022-06-14 2026-07-01 Invenra Inc Multi-species liaison agents targeting B7H3 and GD2, and their uses

Also Published As

Publication number Publication date
JP7840312B2 (ja) 2026-04-03
JP2023536631A (ja) 2023-08-28
US20240010751A1 (en) 2024-01-11
WO2022031710A3 (en) 2022-03-31
CN116390939A (zh) 2023-07-04
WO2022031710A2 (en) 2022-02-10
EP4192878A4 (en) 2025-04-16
EP4192878A2 (en) 2023-06-14
CA3188068A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
US20250197502A1 (en) Multispecific binding agents and uses thereof
AU2012245477B2 (en) Antibodies and other molecules that bind B7-H1 and PD-1
US20240010751A1 (en) Multispecific binding agents and uses thereof
TW202210514A (zh) 針對tigit的抗體
EP3743081A1 (en) Antibodies specific to delta 1 chain of t cell receptor
US20250326858A1 (en) 5t4 binding agents and uses thereof
US20230357391A1 (en) Cd47 binding agents and uses thereof
US20230303699A1 (en) Pd-l1 binding agents and uses thereof
CN118974098A (zh) 多重特异性结合剂及其用途
WO2025230866A1 (en) Anti-alpha5 integrin antibodies and uses thereof